Capha Pharmaceuticals Inc.

Equities

FPSUF

CA13962W1086

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 12:51:43 2023-02-27 pm EST			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-.--%

May. 30	Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 26	Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

FPS PHARMA INC. Appoints Kyle J. Remenda as President and Chief Operating Officer

January 16, 2017 at 01:39 pm EST

FPS PHARMA INC. appointed Kyle J. Remenda as president and chief operating officer.

Latest news about Capha Pharmaceuticals Inc.

Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 30	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 26	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Capha Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	23-04-25	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-26	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-27	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-29	CI
Capha Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	22-04-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-30	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-30	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-29	CI
Mill City Gold Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2018	18-11-28	CI

Chart Capha Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Capha Pharmaceuticals Inc. is a Canada-based company. The Company is engaged in exploring various opportunities in the medical technology space.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CAPHA PHARMACEUTICALS INC.	-.--%	64
ELI LILLY AND COMPANY	+55.32%	819B
JOHNSON & JOHNSON	-6.75%	351B
MERCK & CO., INC.	+13.56%	329B
ABBVIE INC.	+10.68%	298B
ASTRAZENECA PLC	+16.57%	242B
ROCHE HOLDING AG	+2.04%	225B
NOVARTIS AG	+13.31%	217B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	158B

Other Pharmaceuticals